Waters Corp to Buy Bioscience and Diagnostics Unit Becton in $17.5 Billion Deal

BD in February revealed its intention to separate the biosciences and diagnostics business, which generated $3.4 billion in revenue in BD’s 2024 financial year.

The merger with Waters creates a combined company with expected 2025 sales of about $6.5 billion.

Under the agreement, BD shareholders will own about 39.2% of the combined company and Waters the other 60.8%. BD will also receive a cash distribution of about $4 billion before the combination is completed. Waters is expected to assume approximately $4 billion of debt.

Read more at MedTechDive